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Pulmonary arterial hypertension (PAH) is a severe and 
chronic disease characterized by a progressive obstructive 
remodeling of the distal pulmonary arteries that results in in-
creased pulmonary vascular resistance and pulmonary arte-
rial pressure. PAH includes a heterogeneous group of clinical 
entities such as idiopathic PAH (IPAH), heritable PAH (HPAH), 
drug- and toxin-induced PAH, and PAH associated with con-
genital heart disease, connective tissue disease (CTD), and 
HIV infection (1).
The exact processes that initiate the pathological changes 
seen in PAH are largely unknown. It is hypothesized that the 
interaction between constitutional predisposition and envi-
ronmental risk factors may be involved in the initial stages 
of the disease. However, the exact role of the autoantibod-
ies in CTD or the viral involvement in HIV infection on the 
pathogenesis of associated PAH is unclear. It appears that a 
specific injury on the vessel wall of distal pulmonary arter-
ies may initiate, in predisposed individuals, a pathobiological 
cascade of events leading to a common final pathological ob-
structive condition. Pathological lesions in PAH patients affect 
the distal pulmonary arteries (<500 µm of diameter) and are 
characterized by medial hypertrophy, intimal proliferative 
and fibrotic changes, adventitial thickening with moderate 
perivascular inflammatory infiltrates, complex lesions (plex-
iform and dilated), and also thrombotic lesions (2).
It is unclear whether thrombotic vascular lesions are an 
integral part of the pulmonary vascular pathology or are sim-
ply an epiphenomenon. In early pathological series, a high 
prevalence of vascular thrombotic lesions at postmortem 
examination were described in patients diagnosed as IPAH 
(3). However, it is uncertain whether the differential diagno-
sis with chronic thromboembolic pulmonary hypertension 
(CTEPH) was performed according to the modern criteria (1). 
There is some biological rationale to support the hypothesis 
that thrombotic processes are a significant pathophysiologic 
feature of PAH and that its evolution contributes to disease 
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progression (4). However, these abnormalities apparently 
have not been described in the associated forms of PAH, in-
cluding CTD-PAH.
PAH is a common complication of systemic sclerosis 
(SSc), relatively uncommon in mixed CTD and systemic lupus 
erythematosus and rare in rheumatoid arthritis, Sjogren’s 
syndrome, and inflammatory myositis (5). Patients with 
CTD-PAH, especially with PAH-SSc, have been included in 
many of the randomized controlled trials with drugs in PAH, 
and usually, they represent the second largest group after 
IPAH. Several studies demonstrate that CTD-PAH patients have 
a worse prognosis as compared with other PAH subgroups and 
that patients with SSc-PAH have particularly poor outcomes 
(6). Nevertheless, the advanced PAH therapies determine im-
provements in clinical, haemodynamic, and exercise capacity 
measures as well as health-related quality-of-life outcomes, 
also in SSc-PAH patients compared with placebo (7, 8).
Oral anticoagulant treatment has been indicated for pa-
tients with IPAH, HPAH, and PAH due to anorexigens in differ-
ent editions of the pulmonary hypertension (PH) guidelines 
with variable degrees of recommendation. Supporting evidence 
and safety data, however, are limited. In fact, only eight obser-
vational studies (two prospective and six retrospective) have 
evaluated the effect of chronic anticoagulation on the outcome 
of patients with IPAH, and six of them reported apparently favor-
able outcomes (3, 9-15). In 2006, a qualitative systematic review 
on anticoagulation in PAH performed by Johnson concluded that 
the literature appears to support a treatment effect of anticoag-
ulation therapy with warfarin on mortality in IPAH but requiring 
randomized clinical trials (16). In fact, none of the studies was 
blinded, randomized, and placebo-controlled. Second, the stud-
ies date to a time when there was no specific therapy for PAH 
(only empiric use of vasodilators) and the size of the sample was 
extremely poor. Benefit of oral anticoagulation in CTD-PAH is 
even less clear as this strategy has been extrapolated from the 
questionable data collected in IPAH patients (17).
A Bayesian analysis of observational data from a longi-
tudinal cohort of patients with SSc-PAH or IPAH concluded 
that there is a low probability that warfarin improves sur-
vival in SSc-PAH and IPAH. Given the availability of multiple 
PAH therapies with evidence-based clinical benefits, the po-
tential additional effect of warfarin to improve outcomes is 
unclear if any (18).
Recently, a comparative prospective registry-based 
study (COMPERA) apparently showed that IPAH anticoag-
ulated patients had a better survival as compared to non- 
anticoagulated ones. No survival benefit was observed in 
patients with PAH associated with other conditions like 
CTD-PAH (14). In this population, there is a trend (p = 0.08) 
towards a worse outcome associated with anticoagulation 
(14). However, the analysis performed in this study is influ-
enced by the “immortal time bias” and even the favorable 
effect observed in IPAH patients is questionable (19). In 
fact, the survival in this study was computed since the inclu-
sion of the patients in the registry and not since the actual 
starting of the anticoagulant therapy. The time between 
table I - Recent studies of anticoagulation therapy in PAH
Author Subjects Exposure Outcome
Olsson et al. (14) COMPERA registry 1283 Vitamin K antagonists, 
heparins, and novel oral 
anticoagulation
 
  IPAH (n = 800) Better 3-year survival (p = 0.006) in 
patients on anticoagulation compared 
with patients who never received 
anticoagulation
  SSc-PAH (n = 208) Trend (p = 0.08) towards a worse out-
come associated with anticoagulation
Preston et al. (20) REVEAL registry 
(matched study)
374 Vitamin K antagonist  
  IPAH (n = 288) No survival difference with warfarin 
in IPAH patients in comparison with 
matched controls.
  SSc-PAH (n = 86) No survival difference with warfarin in 
SSc-PAH patients in comparison with 
matched controls.
Galie et al. (21) SERAPHIN trial 742 (379 on anticoag-
ulation therapy and 
363 no)
Vitamin K antagonist No significant difference in the risk of 
morbidity and mortality observed in 
patients not on anticoagulant therapy 
compared with those on anticoagulant 
therapy between IPAH and non-IPAH 
patients
IPAH = idiopathic pulmonary arterial hypertension; SSc = systemic sclerosis.
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these two time-points is defined “immortal time” because 
the patient cannot die before receiving the first dose of anti-
coagulant therapy. In the study analysis, the “immortal time” 
was considered as survival on anticoagulant therapy thus in-
appropriately providing this survival extension to the treated 
patients as compared with the non-anticoagulated ones 
(19). In the REVEAL registry analysis, this bias was avoided 
and no significant survival increase was observed in IPAH 
patients who started warfarin while in the registry. In addi-
tion, in SSc-PAH patients, long-term warfarin treatment was 
associated with worse survival as compared with patients 
not receiving warfarin even after adjusting for confounders 
(20). Immortal time bias was avoided also in the compari-
son of PAH patients with or without anticoagulant treat-
ment enrolled in the SERAPHIN trial, and no difference in 
the outcome was observed in patients not on anticoagulant 
therapy compared with those on anticoagulant therapy be-
tween IPAH and non-IPAH patients (IPAH—hazard ratio (HR): 
0.97, 0.72–1.32 vs non-IPAH—HR: 0.71, 0.49–1.02; p = 0.19) 
(21). Newest studies evaluating a role for anticoagulation 
in PAH, with mortality as an end point, are summarized in 
Tab. I. The detrimental effect of long-term warfarin in CT-
D-PAH patients may be explained by comorbidities. In fact, 
there is increased risk of bleeding from gastrointestinal te-
langiectasias or arteriovenous malformations in SSc-associ-
ated PAH patients as compared to IPAH or CTEPH patients 
(22, 23). In fact, in the retrospective analysis of PAH patients 
treated in the VU Medical Center hospital of Amsterdam, 
bleeding event rates with vitamin K antagonist drugs were 
5.4 per 100 patient-years in patients with IPAH, 19 per 100 
patient-years in CTD-PAH patients, and 2.4 per 100 patient-
years in CTEPH patients (23). Major bleedings were indepen-
dent of age, sex, target international normalized ratio (INR) 
range, documented INR actual value, vitamin K antagonist 
type, or right atrial pressure, but was associated with the 
concomitant use of prostacyclin analogues (23). In fact, the 
concurrent use of PAH-specific therapies with antiplatelet ef-
fect such as prostacyclin analogues may increase the risk of 
bleeding for the combined inhibition on multiple factors of 
the coagulation cascade.
A randomized controlled trial with the new oral anticoag-
ulant apixaban in SSc-PAH patients (SPHInX registration num-
ber ACTRN12614000418673) is ongoing and may provide us 
with long awaited information on this treatment approach. In 
fact, this is the first clinical trial ever to evaluate the efficacy, 
safety, and cost-effectiveness of anticoagulant therapy in ad-
dition to approved PAH drugs in SSc-PAH patients (24).
In conclusion, the use of anticoagulant treatment re-
mains controversial in patients with PAH and may be det-
rimental in the majority of patients with CTD-PAH. Antico-
agulant treatment may be considered in conditions with PH 
and increased thrombophilia like in the presence of lupus 
anticoagulant phenomenon or in the presence of anticard-
iolipin antibodies.
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